Hydrogen Sulfide

Hydrogen Sulfide

SCHEMBL846933

[26SH2]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21525610 0.58
Water SCHEMBL25437472 0.00
SCHEMBL25434707 0.00
SCHEMBL23644895 0.00
Potassium Ion SCHEMBL23462161 0.00 CA4 (0.50)
SCHEMBL25396888 0.00
SCHEMBL25438576 0.00
Methane SCHEMBL23929073 0.00
SCHEMBL25436537 0.00
Potassium Ion SCHEMBL23462037 0.00 CA4 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4352233-A1 CRISPR-TRANSPOSON SYSTEMS FOR DNA MODIFICATION The Trustees of Columbia University in the City of New York (US) 2024-04-17 EP disclosed
WO-2024025895-A2 AIR CONTACTOR BALTIMORE AIRCOIL COMPANY, INC. (US) 2024-02-01 WO disclosed
WO-2022261122-A1 CRISPR-TRANSPOSON SYSTEMS FOR DNA MODIFICATION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-15 WO disclosed
WO-2021126553-A1 IN-SITU ADDITIVE IMPLANTS WARSAW ORTHOPEDIC, INC (US) 2021-06-24 WO disclosed
EP-3818161-A1 TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND DISORDERS ASSOCIATED WITH THE SPINAL CORD Voyager Therapeutics, Inc. (US) 2021-05-12 EP disclosed
EP-3793616-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AAV Voyager Therapeutics, Inc. (US) 2021-03-24 EP disclosed
EP-3737233-A1 GROWTH FACTOR OTIC FORMULATIONS Otonomy, Inc. (US) 2020-11-18 EP disclosed
EP-3707149-A1 SELENOGALACTOSIDE COMPOUNDS FOR THE TREATMENT OF SYSTEMIC INSULIN RESISTANCE DISORDERS AND THE USE THEREOF Galectin Sciences, LLC (US) 2020-09-16 EP disclosed
EP-3707266-A1 TARGETED INTEGRATION SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES Editas Medicine, Inc. (US) 2020-09-16 EP disclosed
EP-3694520-A1 COMPOSITIONS AND METHODS FOR TREATING DIFFUSE LARGE B CELL LYMPHOMA Merck Sharp & Dohme Corp. (US) 2020-08-19 EP disclosed
EP-2023930-A1 IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2009-02-18 EP disclosed
WO-2008020866-A1 IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON 2008-02-21 WO disclosed
WO-2007139653-A1 LCD FILMS OR SHEETS COMPRISING FILMS COMPRISING POLYESTER COMPOSITIONS FORMED FROM 2,2,4,4,-TETRAMETHYL-1,3-CYCLOBUTANEDIOL AND 1,4-CYCLOHEXANEDIMETHANOL EASTMAN CHEMICAL COMPANY (US) 2007-12-06 WO disclosed
WO-2007139663-A1 POLYESTER COMPOSITIONS WHICH COMPRISE CYCLOBUTANEDIOL AND CERTAIN THERMAL STABILIZERS, AND/OR REACTION PRODUCTS THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-12-06 WO disclosed
WO-2007098184-A2 METHODS AND COMPOSITIONS FOR ANALYTE DETECTION NANOGEN, INC. (US) 2007-08-30 WO disclosed
EP-1809214-A2 CROSSBAR SPINAL PROSTHESIS HAVING A MODULAR DESIGN AND SYSTEM FOR TREATING SPINAL PATHOLOGIES ARCHUS ORTHOPEDICS INC. (US) 2007-07-25 EP disclosed
WO-2007075836-A2 METHODS FOR DETECTION OF GENETIC DISORDERS RAVGEN, INC. (US) 2007-07-05 WO disclosed
EP-1765789-A1 N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER Novartis Vaccines and Diagnostics, Inc. (US) 2007-03-28 EP disclosed
WO-2006055186-A2 SPINAL PROSTHESIS HAVING A MODULAR DESIGN ARCHUS ORTHOPEDICS, INC. (US) 2006-05-26 WO disclosed
WO-2006002236-A1 N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-01-05 WO disclosed